Hypercalcemia: Etiology, Classification, Diagnosis, and Management

Overview and Pathophysiology

  • Definition of Hypercalcemia:

    • Defined as an abnormally elevated serum calcium concentration, specifically a total serum calcium concentration of >10.5 mg/dL> 10.5\,\text{mg/dL} or an ionized (free) calcium concentration of >5.25 mg/dL> 5.25\,\text{mg/dL}.
    • Primary hyperparathyroidism and malignancy account for approximately 90%90\% of all documented cases.
  • True Hypercalcemia vs. Factitious Hypercalcemia:

    • True Hypercalcemia:
      • Characterized by elevated ionized calcium (↑ionized Ca2+\uparrow \text{ionized Ca}^{2+}) or elevated corrected calcium (↑corrected calcium\uparrow \text{corrected calcium}), irrespective of total serum calcium measurements.
      • Clinically significant and may cause physiological dysfunction and symptomatology.
    • Factitious Hypercalcemia (Pseudohypercalcemia):
      • Characterized by an elevated total serum calcium concentration in the presence of a completely normal ionized calcium level (the non-protein bound, biologically and physiologically active fraction) or a normal albumin-corrected calcium level.
      • Patients are clinically asymptomatic because physiologically active free ionized calcium is maintained within homeostatic limits.
      • Pathogenesis involves elevations in circulating serum proteins that bind calcium, which artificially inflates total calcium levels:
        • Hyperalbuminemia: Commonly observed in severe hemoconcentration or dehydration states.
        • Paraproteinemia: Observed in plasma cell dyscrasias, most notably multiple myeloma, where circulating monoclonal immunoglobulins bind calcium ions.

Etiology and Classification

  • Etiological Classification Overview:

    • Causes are systematically separated into PTH-mediated hypercalcemia (characterized by inappropriately normal or elevated parathyroid hormone levels) and non-PTH-mediated hypercalcemia (characterized by suppressed parathyroid hormone levels due to intact physiological negative feedback).
  • PTH-Mediated Hypercalcemia:

    • Primary Hyperparathyroidism:
      • Etiology: Solitary parathyroid adenoma (∼80–85%\sim 80\text{--}85\% of cases) or diffuse parathyroid hyperplasia (sporadic or associated with familial syndromes such as MEN1 or MEN2A).
      • Pathophysiology: Autonomous oversecretion of parathyroid hormone (PTH\text{PTH}) stimulates renal tubular calcium reabsorption, promotes skeletal calcium mobilization via osteoclastic resorption, and upregulates the renal expression of 1α-hydroxylase1\alpha\text{-hydroxylase}, leading to increased synthesis of 1,25-dihydroxyvitamin D1,25\text{-dihydroxyvitamin D} (calcitriol\text{calcitriol}) in the proximal tubules, which in turn enhances intestinal calcium and phosphate absorption.
      • Clinical Course: Usually mild, insidious, and asymptomatic; detected incidentally on routine biochemical profiling.
    • Tertiary Hyperparathyroidism:
      • Etiology: Advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD).
      • Pathophysiology: Longstanding, untreated secondary hyperparathyroidism leads to chronic parathyroid gland hyperplasia and subsequent monoclonal transformation, resulting in autonomous, nonsuppressible parathyroid hormone secretion independent of serum calcium concentrations.
    • Familial Hypocalciuric Hypercalcemia (FHH):
      • Inactivating genetic defects in calcium sensing.
    • Medication-Induced (Lithium):
      • Reduces renal calcium excretion and shifts the set point of the calcium-sensing receptor (CaSR\text{CaSR}) rightward in the parathyroid glands, requiring higher serum calcium levels to inhibit parathyroid hormone secretion.
  • Non-PTH-Mediated Hypercalcemia:

    • Hypercalcemia of Malignancy:
      • Typically manifests acutely with severe, symptomatic elevations in serum calcium.
      • Paraneoplastic PTHrP Secretion: Most common cause (∼80%\sim 80\% of malignancy-associated cases). Malignant cells secrete parathyroid hormone-related protein (PTHrP\text{PTHrP}), which binds and activates the shared PTH/PTHrP receptor (PTH1R), mimicking parathyroid hormone action on bone and kidneys. Common etiologies include squamous cell carcinomas (lung, head and neck), renal cell carcinoma, bladder cancer, and ovarian cancer.
      • Osteolytic Metastases: Direct osteolytic tumor invasion accompanied by local cytokine production (e.g., RANKL, TNF, IL-1) driving excessive osteoclastic bone resorption. Common etiologies include multiple myeloma, breast cancer, lymphoma, leukemia, and renal cell carcinoma.
      • Paraneoplastic Production of Calcitriol: Extra-renal synthesis of active 1,25-dihydroxyvitamin D1,25\text{-dihydroxyvitamin D} by tumor tissue. Common etiologies include Hodgkin and non-Hodgkin lymphomas, as well as ovarian dysgerminoma.
    • Granulomatous Disorders:
      • Etiologies include sarcoidosis, tuberculosis, berylliosis, and fungal granulomas.
      • Pathophysiology: Unregulated expression of 1α-hydroxylase1\alpha\text{-hydroxylase} within activated mononuclear cells and macrophages inside granulomas catalyzes conversion of 25-hydroxyvitamin D25\text{-hydroxyvitamin D} to 1,25-dihydroxyvitamin D1,25\text{-dihydroxyvitamin D} independent of parathyroid hormone or negative feedback regulation.
    • Medications and Intoxications:
      • Thiazide Diuretics: Inhibit the Na+/Cl−Na^+/Cl^- cotransporter in the distal convoluted tubule, indirectly augmenting renal tubular calcium uptake and reducing renal calcium excretion.
      • Exogenous Vitamin D Excess: Toxicity from high-dose ergocalciferol, cholecalciferol, or active metabolites leads to massive hyperabsorption of dietary calcium and phosphate in the small intestine.
      • Exogenous Calcium and Antacids: Chronic excessive ingestion of calcium carbonate or calcium-containing antacids.
      • Vitamin A Toxicity: Excess vitamin A and vitamin A derivatives (such as all-trans retinoic acid) directly stimulate osteoclast activity and induce excessive skeletal resorption.
    • Thyrotoxicosis:
      • Elevated thyroid hormones (T3\text{T}_3 and T4\text{T}_4) directly stimulate osteoclasts, causing increased bone turnover, osteoclastic bone resorption, and skeletal demineralization.
    • Long Periods of Immobilization:
      • Lack of mechanical weight-bearing stress suppresses osteoblastic bone formation while shifting bone remodeling toward uncoupled osteoclastic resorption, leading to demineralization and hypercalcemia.
      • Predominantly affects individuals with baseline high bone turnover states, such as growing adolescents, young adults, or patients with underlying Paget disease of bone.
    • Milk-Alkali Syndrome:
      • Historically or modernly caused by the consumption of large amounts of calcium supplements combined with absorbable alkali (such as calcium carbonate).
      • Characterized clinically and biochemically by the classical triad of hypercalcemia, metabolic alkalosis, and renal insufficiency/acute kidney injury.
    • Adrenal Insufficiency (Addison Disease):
      • Proposed pathophysiological mechanisms:
        • Hypovolemia and extracellular volume depletion lead to decreased glomerular filtration rate (↓GFR\downarrow \text{GFR}), resulting in diminished filtered calcium load and a compensatory increase in proximal tubular calcium reabsorption.
        • Increased 1α-hydroxylase1\alpha\text{-hydroxylase} activity leading to increased circulating calcitriol (↑calcitriol\uparrow \text{calcitriol}).
        • Decreased stanniocalcin levels (↓stanniocalcin\downarrow \text{stanniocalcin}), removing an inhibitory regulator of calcium uptake.
  • Etiology Mnemonic: "Thinking Chimpanzees!":

    • Thinking: Thiazides, Thyroid (Thyrotoxicosis)
    • C: Calcium supplementation
    • H: Hyperparathyroidism (Primary or Tertiary)
    • I: Immobilization, Inherited (Familial Hypocalciuric Hypercalcemia)
    • M: Milk-alkali syndrome, Meds (Lithium, Thiazides)
    • P: Paraneoplastic PTHrP
    • A: Adrenal insufficiency
    • N: Neoplasm (Multiple myeloma, breast, lung, leukemia, lymphoma)
    • Z: Zollinger-Ellison syndrome (associated with MEN1 / primary hyperparathyroidism)
    • E: Excessive vitamin D
    • E: Excessive vitamin A
    • S: Sarcoidosis & granulomatous diseases

Clinical Features and Severity Classification

  • Organ System Clinical Features:

    • Renal and Urological Manifestations:
      • Nephrolithiasis and nephrocalcinosis (calcium oxalate stones are more frequent than calcium phosphate stones).
      • Polyuria and secondary polydipsia caused by calcium-induced nephrogenic diabetes insipidus (impaired aquaporin-2 expression and direct blunting of antidiuretic hormone / ADH sensitivity in the collecting ducts).
      • Dehydration, prerenal azotemia, oliguria, or anuria in advanced crisis.
    • Musculoskeletal Manifestations:
      • Diffuse bone pain, arthralgias, and myalgias.
      • Pathological fractures and osteopenia/osteoporosis due to enhanced osteoclastic demineralization.
    • Gastrointestinal Manifestations:
      • Constipation (due to decreased gastrointestinal smooth muscle contractility).
      • Abdominal pain, nausea, vomiting, and anorexia.
      • Peptic ulcer disease (calcium directly stimulates gastrin release from G cells, promoting gastric acid secretion).
      • Acute pancreatitis (calcium deposition in pancreatic ducts and premature intrapancreatic trypsinogen activation).
    • Neuropsychiatric Manifestations:
      • Early features: Anxiety, depression, fatigue, psychomotor slowing, and cognitive impairment.
      • Severe progression: Lethargy, somnolence, delirium, psychosis, obtundation, and coma (pathognomonic of hypercalcemic crisis).
    • Neuromuscular and Cardiovascular Manifestations:
      • Diminished neuromuscular and smooth muscle excitability leading to skeletal muscle weakness, hyporeflexia, and paresis.
      • Shortened QT interval on electrocardiography.
      • Arrhythmias and severe bradycardia.
      • Appearance of Osborn waves (J waves\text{J waves}) in severe hypercalcemic states.
  • Severity Stratification and Clinical Pearls:

    • Mild Hypercalcemia:
      • Total serum calcium: 10.5–12 mg/dL10.5\text{--}12\,\text{mg/dL}.
      • Ionized calcium: 5.25–8 mg/dL5.25\text{--}8\,\text{mg/dL}.
      • Clinical presentation: Typically asymptomatic; may exhibit subtle constitutional symptoms.
    • Moderate Hypercalcemia:
      • Total serum calcium: 12–14 mg/dL12\text{--}14\,\text{mg/dL}.
      • Ionized calcium: 8–10 mg/dL8\text{--}10\,\text{mg/dL}.
      • Clinical presentation: May be well-toler